Business|May 20, 2026|2 min read

Drugmakers guard IP more tightly amid China competition

Pharmaceutical companies are increasing intellectual property protections in response to rising competition from China's expanding drug pipeline, according to biotech industry reporting from STAT's Breakthrough Summit West.

#pharmaceutical-patents#intellectual-property#china-competition#drug-development#biotech-industry#fda-leadership#parabilis-medicines#ipo#drug-market

STAT News

Contributor

Drugmakers guard IP more tightly amid China competition

The FDA's new path, the status of animal testing, and other biotech news from The Readout

News from The Readout Newsletter

Parabilis Medicines has submitted its application to go public, seeking to list under the ticker symbol PBLS.

Former FDA chief expresses optimism about agency's new direction

Former FDA commissioner David Kessler has expressed "great confidence" in Kyle Diamantas, the newly appointed interim FDA chief following the departure of Marty Makary.

This article covers significant updates in the biotech industry, including changes in FDA leadership, recent IPO applications, and insights drawn from STAT's Breakthrough Summit West.

Share this story

McKinsey studied 200 family business successions. The biggest problem wasn't the heir — it was the outgoing CEO

McKinsey research analyzing 200 family-owned businesses reveals that CEO succession failures stem primarily from outgoing leaders, not incompetent heirs. The study shows that poorly managed transitions destroy an estimated $1 trillion in market value globally annually.